Valuation: Apogee Therapeutics, Inc.

Market Cap 10.04B 8.78B 8.1B 7.44B 14.1B 966B 14.35B 96.67B 37.93B 472B 37.7B 36.88B 1,628B P/E 2026 *
-31x
P/E 2027 * -24x
Enterprise Value 9.06B 7.92B 7.31B 6.72B 12.73B 872B 12.95B 87.24B 34.23B 426B 34.03B 33.28B 1,469B EV / Sales 2026 *
997x
EV / Sales 2027 * 744x
Free-Float
90.78%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Apogee Therapeutics, Inc.

1 day+0.25%
1 week+0.56%
Current month+1.18%
1 month+52.03%
3 months+51.79%
6 months+62.91%
Current year+77.91%
1 week 133.3
Extreme 133.3
134.31
1 month 84.01
Extreme 84.01
134.31
Current year 60.35
Extreme 60.35
134.31
1 year 34.34
Extreme 34.34
134.31
3 years 14.19
Extreme 14.19
134.31
5 years 14.19
Extreme 14.19
134.31
10 years 14.19
Extreme 14.19
134.31
Manager TitleAgeSince
Chief Executive Officer 36 31/08/2022
Director of Finance/CFO 60 31/12/2022
Chief Tech/Sci/R&D Officer - 30/04/2023
Director TitleAgeSince
Director/Board Member 54 21/06/2023
Director/Board Member 62 31/05/2023
Director/Board Member 36 31/05/2023
Date Insider Type Main position Quantity % Market Cap.
07-09Don

Chief Executive Officer

-75,046 0.1340%
06-30Fiscal year

Chief Technology Officer

13,750 0.0246%
06-21Sell

Chief Executive Officer

-80,000 0.1429%
Change 5-day change 1-year change 3-year change Capi.($)
+0.25%+0.56%+245.40%+532.55% 10.04B
-0.17%+1.22%+2.98%+6.80% 50.35B
-0.29%-3.16%+380.69%+591.82% 39.32B
-0.49%-0.68%+29.15%-6.46% 34.69B
+1.53%+0.74%+23.45%+58.54% 34.08B
+1.68%-1.40%+4.23%+27.34% 26.63B
+1.13%+0.60% - - 16.49B
-1.29%-3.12%+65.20%+117.60% 15.31B
+0.43%+0.55%+15.19%+17.46% 13.8B
+2.45%+1.99%+15.09%-30.12% 12.87B
Average +0.52%-0.33%+86.82%+146.17% 25.36B
Weighted average by Cap. +0.39%-0.29%+88.19%+139.67%

Financials

2026 *2027 *
Net sales 9.09M 7.95M 7.33M 6.74M 12.77M 875M 12.99M 87.53M 34.35M 428M 34.14M 33.39M 1.47B 12.5M 10.93M 10.08M 9.27M 17.56M 1.2B 17.86M 120M 47.22M 588M 46.94M 45.91M 2.03B
Net income -318M -278M -256M -235M -446M -30.55B -454M -3.06B -1.2B -14.93B -1.19B -1.17B -51.47B -416M -364M -336M -309M -585M -40.07B -595M -4.01B -1.57B -19.59B -1.56B -1.53B -67.51B
Net Debt -980M -856M -790M -726M -1.38B -94.25B -1.4B -9.43B -3.7B -46.07B -3.68B -3.6B -159B -740M -647M -597M -549M -1.04B -71.23B -1.06B -7.13B -2.8B -34.81B -2.78B -2.72B -120B
Logo Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
Employees
261
Date Price Change Volume
15/07/26 US$134.29 +0.25% 605,990
14/07/26 US$133.96 +0.10% 1,365,160
13/07/26 US$133.82 +0.13% 1,009,120
10/07/26 US$133.65 +0.06% 787,824
09/07/26 US$133.57 +0.24% 2,057,373
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
134.29USD
Average target price
130.53USD
Spread / Average Target
-2.80%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APGE Stock